ABSTRACT
Therapeutic monoclonal antibodies have become a signicant component of the pharmaceuticals market and are projected to increase in the future.1 The development of hybridoma technology, rst described by Köhler and Milstein in 1975,2 was the key advancement that ultimately led to the development of antibodybased drugs. Hybridoma technology proved to be an efcient means to isolate single-specicity antibodies and produce them in unlimited amounts, thus enabling the characterization and production of antibodies for therapeutic applications. However, hybridoma technology uses immunized rodents as the source of B-cells for producing antibodies, yielding immunogenic proteins when used in human therapy.
